 |
|
|
| |
Once-Daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in Combination With Peginterferon Alfa-2b/Ribavirin (PR) for 12 Weeks Plus 12 Weeks PR in Treatment-Naive Patients With HCV Genotype 1 (G1): SVR Results From NEXT-1, a Phase 2 Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
J. Vierling,1 F. Poordad,2 E. Lawitz,3 R. Ghalib,4 W. M. Lee,5 N. Ravendhran,6 J. Galati,7 B. Bacon,8 S. Flamm,9 L. Balart,10 B. Freilich,11 E. Schiff,12 I. Jacobson,13 P. Kwo,14 S. Gordon,15 M. Sulkowski,16 R. Jiang,17
N. Boparai,17 E. Chaudhri,17 M. Treitel,17 E. Hughes,18 C. Brass,18 J. Albrecht18
1Baylor College of Medicine, Houston, TX; 2Cedars-Sinai Medical Center, Los Angeles, CA; 3Alamo Medical Research, San Antonio, TX; 4The Liver Institute at Methodist Dallas, Dallas, TX; 5University of Texas Southwestern Medical Center, Dallas, TX; 6Digestive Disease Associates, Baltimore, MD;
7Liver Specialists of Texas, Houston, TX; 8Saint Louis University School of Medicine, St. Louis, MO; 9Northwestern Feinberg School of Medicine, Chicago, IL; 10Tulane University Health Sciences Center, New Orleans, LA; 11Kansas City Gastroenterology and Hepatology, Kansas City, MO;
12University of Miami Center for Liver Diseases, Miami, FL; 13Weill Cornell Medical College, New York, NY; 14Indiana University School of Medicine, Indianapolis, IN; 15Henry Ford Hospital, Detroit, MI; 16Johns Hopkins Rockland Physicians Practice and Research Group, Greenspring Station, MD;
17Merck Sharp & Dohme Corp., Whitehouse Station, NJ; 18Former employee of Merck Sharp & Dohme Corp., Whitehouse Station, NJ
|
| |
|
|
|
|
|
